Zenas BioPharma, Inc. (ZBIO) stock
ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$26.42−1.33 (-4.79%)
Close on Nov 18, 2026Market cap $1.72BP/E –Yield –
Zenas BioPharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Zenas BioPharma's operating income for the twelve months ending Sep 30, 2026 was -$526.40M. For fiscal 2025 it was -$383.06M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$383.06M | – |
| FY2024 | Dec 31, 2024 | -$163.89M | – |
| FY2023 | Dec 31, 2023 | -$37.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$103.41M | – |
| Q2 FY2026 | Jun 30, 2026 | -$107.66M | – |
| Q1 FY2026 | Mar 31, 2026 | -$77.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$237.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$52.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$37.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.98M | -215.0% |
| Q2 FY2024 | Jun 30, 2024 | -$39.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$27.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.78M | – |
| Q3 FY2023 | Sep 30, 2023 | $35.62M | – |
See a number that looks wrong?